MeiraGTx reacquires bota-vec from Johnson & Johnson to advance gene therapy for XLRP, supported by Phase 3 data showing meaningful vision improvements.
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
Acquisition and Regulatory Strategy
MeiraGTx Holdings plc has reacquired full rights to botaretigene sparoparvovec (bota-vec) from Johnson & Johnson under an asset purchase agreement, bringing the gene therapy back under its direct control after previously collaborating with Johnson & Johnson on its development. The move positions the company to independently advance bota-vec for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease with no approved treatments.
Alexandria Forbes, CEO of MeiraGTx, stated that the deal enables advancement of a late-stage asset with demonstrated clinical benefit in a population with urgent unmet need, supported by the company’s prior development involvement and regulatory readiness. The company plans to initiate filings in the United States, European Union, and Japan, with a potential launch targeted for 2027.
Phase 3 Clinical Outcomes
Clinical data from the Phase 3 LUMEOS trial (NCT04671433) showed that while the primary endpoint assessing visual mobility did not reach statistical significance, treated patients demonstrated directional improvement compared to controls.
Secondary outcomes showed statistically significant and clinically meaningful improvements across multiple measures, including low luminance visual acuity, retinal sensitivity, and patient-reported functional vision such as mobility and dim-light performance. A notable proportion of treated patients achieved improvements across multiple vision domains, and the therapy maintained a manageable safety profile with no new safety signals.
Expert and Stakeholder Perspectives
The Foundation Fighting Blindness emphasized the urgent need for effective treatments in XLRP and highlighted improvements observed in both objective and patient-reported outcomes.
Investigators, including clinicians from Mass Eye and Ear, reported meaningful real-world functional gains among patients and indicated that the findings support further regulatory evaluation.
XLRP affects more than 20,000 patients across the U.S. and EU and typically leads to progressive vision loss and early blindness.
Financial Terms and Commercial Outlook
Under the agreement, MeiraGTx will pay $25 million upfront, along with a milestone tied to U.S. approval and sales performance, and royalties on global net sales beginning in 2029. The therapy has received Fast Track and Orphan Drug designations in the U.S., and PRIME and ATMP designations in the EU. With established manufacturing capabilities and available commercial inventory, the company aims to transition toward commercialization while advancing its broader pipeline targeting high unmet medical needs
Reference
About the Writer
Vennela Reddy, BPharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.
